29 May 2024 --- Johnson & Johnson signs a definitive agreement with Numab Therapeutics to acquire the rights to a clinical-stage bispecific antibody that could address patient needs in atopic dermatitis (AD). The all-cash transaction is worth approximately US$1.25 billion. The “first-in-class” bispecific antibody, NM26, targets two clinically proven pathways in AD — IL-4R alpha subunit (IL-4Rα) and IL-31. NM26 has the potential to offer distinctive benefits versus existing treatments and address critical unmet needs for AD patients. Johnson & Johnson says it is committed to developing differentiated bispecific antibodies for treating AD and other immune-mediated diseases.
